Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 47,534 shares of the firm's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $50.25, for a total transaction of $2,388,583.50. Following the transaction, the chief executive officer owned 190,126 shares of the company's stock, valued at approximately $9,553,831.50. This trade represents a 20.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Andrew Dudum also recently made the following trade(s):
- On Wednesday, July 16th, Andrew Dudum sold 2,792 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.58, for a total value of $141,219.36.
- On Tuesday, June 17th, Andrew Dudum sold 65,110 shares of Hims & Hers Health stock. The shares were sold at an average price of $59.22, for a total transaction of $3,855,814.20.
- On Monday, June 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.51, for a total transaction of $2,686,146.34.
- On Monday, June 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.76, for a total transaction of $7,272,488.52.
- On Friday, May 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.25, for a total value of $2,768,855.50.
- On Friday, May 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.40, for a total value of $7,482,616.80.
- On Tuesday, April 29th, Andrew Dudum sold 50,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.39, for a total value of $1,819,500.00.
Hims & Hers Health Stock Performance
Shares of HIMS traded up $0.37 during trading hours on Friday, hitting $50.36. 22,036,786 shares of the company were exchanged, compared to its average volume of 24,108,723. The firm's 50 day moving average is $53.86 and its 200-day moving average is $41.62. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98. The company has a market cap of $11.27 billion, a PE ratio of 72.99, a PEG ratio of 1.91 and a beta of 2.02.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The business's quarterly revenue was up 110.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 EPS. As a group, equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Institutional Trading of Hims & Hers Health
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Farallon Capital Management LLC boosted its position in shares of Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after acquiring an additional 8,364,000 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after purchasing an additional 4,145,305 shares during the last quarter. Vanguard Group Inc. raised its stake in Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the last quarter. Nuveen LLC acquired a new stake in Hims & Hers Health in the 1st quarter worth $58,403,000. Finally, Renaissance Technologies LLC grew its position in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after purchasing an additional 1,562,302 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. Truist Financial lifted their target price on Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a research note on Thursday. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. TD Cowen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their target price for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Bank of America upped their price target on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a research note on Tuesday, April 29th. Finally, UBS Group set a $30.00 target price on Hims & Hers Health in a research report on Monday, June 23rd. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $39.83.
Read Our Latest Analysis on HIMS
About Hims & Hers Health
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
